TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy Type II and III Treated With Valproic Acid
Brief Summary: The purpose of this study is to determine if the treatment with valproic acid can increase the muscle strength and motor ability of children with spinal muscular atrophy.


Options:
A: N/A
B: Arm Label: Cohort 1a; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine, Drug: Placebo | Arm Label: Cohort 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): Cohort 1a, Cohort 1b, Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1a
C: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
D: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: AVXS-101 | Intervention Type: BIOLOGICAL; Name: AVXS-101; Assigned to Arm(s): Cohort 1, Cohort 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study: Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents
Brief Summary: This study will investigate whether there is a particular dose of cranberry capsules that is effective in preventing the occurrence of urinary tract infections in females at least 65 years of age or older who live in a nursing home and who have a history of urinary tract infections. The Yale research team will be enrolling 80 subjects in total over several nursing home locations within Connecticut.


Options:
A: Arm Label: 2 cranberry capsules; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 2 cranberry capsules | Arm Label: 2 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 2 cranberry capsules; Assigned to Arm(s): 2 cranberry capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 2 placebo capsules
B: Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cranberry type A pro anthocyandines | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cranberry type A pro anthocyandines; Assigned to Arm(s): Cranberry | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cranberry; Type: EXPERIMENTAL; Interventions: Drug: Cranberry | Intervention Type: DRUG; Name: Cranberry; Assigned to Arm(s): Cranberry | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 3 placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: 1 cranberry capsule & 2 placebo capsules; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo, Dietary Supplement: Cranberry Capsule | Arm Label: 2 cranberry capsules & 1 placebo capsule; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo, Dietary Supplement: Cranberry Capsule | Arm Label: 3 cranberry capsules; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cranberry Capsule | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1 cranberry capsule & 2 placebo capsules, 2 cranberry capsules & 1 placebo capsule, 3 placebo capsules | Intervention Type: DIETARY_SUPPLEMENT; Name: Cranberry Capsule; Assigned to Arm(s): 1 cranberry capsule & 2 placebo capsules, 2 cranberry capsules & 1 placebo capsule, 3 cranberry capsules

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Which is the Optimal Treatment for Miscarriage With a Gestational ac in the Uterus and Which Factors Can Predict if the Treatment Will be Successful?
Brief Summary: The main objective of the study is to determine if there is a difference in the number of women with a complete miscarriage after 10 days between expectant management versus treatment with 800 micrograms of misoprostol intravaginally in women with an an incomplete miscarriage before 14 weeks and a gestational sac retained in the uterus.


Options:
A: Arm Label: Arm A : Operative hysteroscopy; Type: EXPERIMENTAL; Interventions: Procedure: Hysteroscopy | Arm Label: Arm B : Aspirative curettage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Curettage | Intervention Type: PROCEDURE; Name: Hysteroscopy; Assigned to Arm(s): Arm A : Operative hysteroscopy | Intervention Type: PROCEDURE; Name: Curettage; Assigned to Arm(s): Arm B : Aspirative curettage
B: Arm Label: Misoprostol 800 micrograms intravaginally; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: expectant managment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): Misoprostol 800 micrograms intravaginally
C: Arm Label: extra amniotic misoprostol; Type: EXPERIMENTAL; Interventions: Procedure: termination of second trimester pregnancy | Arm Label: vaginal misoprostol; Type: EXPERIMENTAL; Interventions: Procedure: termination of second trimester pregnancy | Intervention Type: PROCEDURE; Name: termination of second trimester pregnancy; Assigned to Arm(s): extra amniotic misoprostol, vaginal misoprostol
D: Arm Label: surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery | Arm Label: misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): misoprostol | Intervention Type: PROCEDURE; Name: surgery; Assigned to Arm(s): surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Which is the Optimal Treatment for Miscarriage With a Gestational ac in the Uterus and Which Factors Can Predict if the Treatment Will be Successful?
Brief Summary: The main objective of the study is to determine if there is a difference in the number of women with a complete miscarriage after 10 days between expectant management versus treatment with 800 micrograms of misoprostol intravaginally in women with an an incomplete miscarriage before 14 weeks and a gestational sac retained in the uterus.


Options:
A: Arm Label: Misoprostol 800 micrograms intravaginally; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: expectant managment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): Misoprostol 800 micrograms intravaginally
B: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Dilapan-S, vitamin B-12 | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Dilapan-S, vitamin B-12; Assigned to Arm(s): 2
D: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Icatibant Outcome Survey (IOS) Registry
Brief Summary: The Icatibant Outcome Survey (IOS) is a prospective, observational disease registry designed to document the routine clinical outcomes over time in participants with angioedema treated with Firazyr® (icatibant) and/or Cinryze® (C1 inhibitor \[human\]) in countries where it is currently approved. The data collected will be used to evaluate the safety of Firazyr (icatibant) and Cinryze (C1 inhibitor \[human\]) in routine clinical practice and as a data source for post-marketing investigations.


Options:
A: Arm Label: DX-2930, Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 | Arm Label: DX-2930, Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 | Arm Label: DX-2930, Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 | Arm Label: DX-2930, Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DX-2930; Assigned to Arm(s): DX-2930, Cohort 1, DX-2930, Cohort 2, DX-2930, Cohort 3, DX-2930, Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Participants with hereditary angioedema (HAE); Type: N/A; Interventions: N/A
C: Arm Label: Part 1: BCX7353 350 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 2 and 3: BCX7353 250 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 2 and 3: BCX7353 125 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Arm Label: Parts 1, 2 and 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part 3: BCX7353 62.5 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 | Intervention Type: DRUG; Name: BCX7353; Assigned to Arm(s): Part 1: BCX7353 350 mg once daily, Part 3: BCX7353 62.5 mg once daily, Parts 2 and 3: BCX7353 125 mg once daily, Parts 2 and 3: BCX7353 250 mg once daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Parts 1, 2 and 3: Placebo
D: Arm Label: BCX4161 300 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161, Drug: Placebo | Arm Label: BCX4161 500 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161 | Arm Label: Placebo three times daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCX4161; Assigned to Arm(s): BCX4161 300 mg three times daily, BCX4161 500 mg three times daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BCX4161 300 mg three times daily, Placebo three times daily

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Investigation of Chest Pain Diagnostic Strategies
Brief Summary: Clinical decision units (CDUs) improve resource utilization and are a recommended care option by the American College of Cardiology / American Heart Association, but are underutilized in non-low risk chest pain patients due to weaknesses of traditional cardiac testing. Cardiac magnetic resonance imaging (CMR) is sensitive and specific for ischemia, can simultaneously assess cardiac function and myocardial perfusion, and could revolutionize the diagnostic process for intermediate risk patients with chest pain. The primary objective of this trial is to measure the efficiency and safety of a combined CDU-CMR care pathway compared to inpatient care among patients with non-low risk acute chest pain.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: OU - Cardiac MRI | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: OU - Conventional Care Testing | Intervention Type: OTHER; Name: OU - Cardiac MRI; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: OU - Conventional Care Testing; Assigned to Arm(s): 2
B: Arm Label: Emergency Department (ED) Observation unit; Type: EXPERIMENTAL; Interventions: Other: Observation unit care, coupled with cardiac MRI | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Observation unit care, coupled with cardiac MRI; Assigned to Arm(s): Emergency Department (ED) Observation unit
C: Arm Label: HEART Pathway; Type: EXPERIMENTAL; Interventions: Other: HEART Pathway | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: HEART Pathway; Assigned to Arm(s): HEART Pathway
D: Arm Label: Inpatient Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CDU-CMR Protocol; Type: EXPERIMENTAL; Interventions: Other: Clinical decision unit care, coupled with cardiac MRI | Intervention Type: OTHER; Name: Clinical decision unit care, coupled with cardiac MRI; Assigned to Arm(s): CDU-CMR Protocol

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study of Effect of One Week Self-management Program in Patients With Fibromyalgia
Brief Summary: The purpose of this study is to explore the effect of one week inpatient self-management program (SMP) in patients with fibromyalgia. The SMP is delivered as group education/activities by allied health professionals.


Options:
A: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
B: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A
C: Arm Label: Tai Chi Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi Intervention | Arm Label: Control Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control Intervention | Intervention Type: BEHAVIORAL; Name: Tai Chi Intervention; Assigned to Arm(s): Tai Chi Intervention | Intervention Type: BEHAVIORAL; Name: Control Intervention; Assigned to Arm(s): Control Intervention
D: Arm Label: Waiting list; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management program; Type: EXPERIMENTAL; Interventions: Behavioral: Self-management program | Intervention Type: BEHAVIORAL; Name: Self-management program; Assigned to Arm(s): Self-management program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment
Brief Summary: The purpose of this study is compare the effects of simvastatin+ezetimibe with those of simvastatin alone on platelet activity, platelet-leukocyte interactions and inflammatory variables in diabetic patients with or without impaired renal function.


Options:
A: Arm Label: standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard therapy | Arm Label: fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): fluvastatin | Intervention Type: DRUG; Name: standard therapy; Assigned to Arm(s): standard therapy
B: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Simvastatin 20mg plus Ezetimibe 10mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Simvastatin 20 mg, Drug: Ezetimibe 10mg | Arm Label: Simvastatin 20mg; Type: OTHER; Interventions: Drug: Simvastatin 20 mg | Intervention Type: DRUG; Name: Simvastatin 20 mg; Assigned to Arm(s): Simvastatin 20mg, Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Ezetimibe 10mg; Assigned to Arm(s): Simvastatin 20mg plus Ezetimibe 10mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: simvastatin + ezetimibe; Type: EXPERIMENTAL; Interventions: Drug: Ezetimibe | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): simvastatin + ezetimibe

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, 28 Day, Three-arm, Parallel Group Study of A0001 in the Treatment of Subjects With Friedreich's Ataxia
Brief Summary: This is a Phase 2a double-blind, placebo-controlled study with two dose levels of A0001 given twice daily for 28 days. Potential subjects will be screened first to determine eligibility, after which they will be randomized to receive either a high dose of A0001, a low dose of A0001 or placebo for 28 days.

Eligible subjects will return within 21 days of screening for the baseline visit and randomization to one of three potential treatments. The subjects will be required to take 3 capsules of study medication in the morning with a morning meal and 3 capsules of study medication at night with an evening meal for 28 days. Additional visits to the clinic are planned for Day 14 and Day 28, at which time a number of clinical and biochemical assessments will be done.


Options:
A: Arm Label: Arm 1 - 900 mg/day Idebenone; Type: EXPERIMENTAL; Interventions: Drug: Idebenone | Arm Label: Arm 2 - up to 2250 mg/day Idebenone; Type: EXPERIMENTAL; Interventions: Drug: Idebenone | Arm Label: Arm 3 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): Arm 1 - 900 mg/day Idebenone | Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): Arm 2 - up to 2250 mg/day Idebenone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3 - Placebo
B: Intervention Type: DRUG; Name: Idebenone; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: electronic diary; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: voice acoustics; Assigned to Arm(s): N/A
D: Arm Label: Low Dose; Type: EXPERIMENTAL; Interventions: Drug: alpha-tocopherolquinone (A0001) | Arm Label: High Dose; Type: EXPERIMENTAL; Interventions: Drug: alpha-tocopherolquinone (A0001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: alpha-tocopherolquinone (A0001); Assigned to Arm(s): Low Dose | Intervention Type: DRUG; Name: alpha-tocopherolquinone (A0001); Assigned to Arm(s): High Dose | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Brief Summary: Patients with type 2 diabetes, obesity, and chronic kidney disease are generally physically inactive, have a high mortality rate, and may benefit from an exercise program. This study seeks to determine if a structured exercise program will benefit the heart (improved exercise tolerance, decreased blood pressure) and/or the kidney (decreased protein loss in urine and stabilization of kidney function) and lead to improvements in diabetes, body composition, and quality of life.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: weight reduction; Type: EXPERIMENTAL; Interventions: Behavioral: weight reduction | Intervention Type: BEHAVIORAL; Name: weight reduction; Assigned to Arm(s): weight reduction
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: IBW; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus extended release | Arm Label: ABW; Type: EXPERIMENTAL; Interventions: Drug: tacrolimus extended release | Intervention Type: DRUG; Name: tacrolimus extended release; Assigned to Arm(s): ABW, IBW
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Bardoxolone Methyl (RTA 402): 75mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Arm Label: Bardoxolone Methyl (RTA 402): 150mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Arm Label: Bardoxolone Methyl (RTA 402): 25mg; Type: EXPERIMENTAL; Interventions: Drug: Bardoxolone Methyl (RTA 402) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bardoxolone Methyl (RTA 402); Assigned to Arm(s): Bardoxolone Methyl (RTA 402): 150mg, Bardoxolone Methyl (RTA 402): 25mg, Bardoxolone Methyl (RTA 402): 75mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: To Study the Safety and Efficacy of G-CSF Therapy on the CD 34 Cell Mobilization and Outcome of Patients With ACLF
Brief Summary: The purpose of the study is to determine whether Granulocyte Colony Stimulating factor(G-CSF) therapy is effective in the treatment of patients with Acute on chronic liver failure(ACLF). The investigators hypothesize that ACLF is a disease where severe hepatic impairment is accompanied by impaired hepatic regeneration. BMC mobilization using G-CSF therapy, or G-CSF therapy per se would increase the regenerative capacity of the liver and shall lead to clinical, biochemical and histological improvements in patients with ACLF.


Options:
A: Arm Label: Granulocyte colony-stimulating factor; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte colony-stimulating factor, Drug: standard treatment | Arm Label: standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard treatment | Intervention Type: DRUG; Name: Granulocyte colony-stimulating factor; Assigned to Arm(s): Granulocyte colony-stimulating factor | Intervention Type: DRUG; Name: standard treatment; Assigned to Arm(s): Granulocyte colony-stimulating factor, standard treatment
B: Arm Label: G-CSF + Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: G-CSF | Arm Label: G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF+Erythropoetin | Intervention Type: DRUG; Name: G-CSF+Erythropoetin; Assigned to Arm(s): G-CSF | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF + Erythropoietin
C: Arm Label: G-CSF group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granulocyte Colony Stimulating Factor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Granulocyte Colony Stimulating Factor; Assigned to Arm(s): G-CSF group | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): Placebo
D: Arm Label: G-CSF+EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF+EPO | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF+EPO; Assigned to Arm(s): G-CSF+EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C